This compound acts as an enzyme inhibitor related to inflammation, specifically demonstrating potential to inhibit 5-lipoxygenase (5-LO), which plays a crucial role in leukotriene production—substances that trigger inflammation in the body. As such, it holds promise for treating chronic inflammatory conditions, including asthma, rheumatoid arthritis, and atopic dermatitis.

Additionally, it exhibits anti-inflammatory activity in cellular and animal models, significantly reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6. This positions it as an attractive candidate for developing novel therapeutics aimed at modulating immune responses in relevant diseases.

Preliminary research indicates low toxicity and acceptable safety profiles in animal studies, suggesting feasibility for progression to human clinical trials.

It is employed in the synthesis of pharmaceutical intermediates and in medicinal chemistry to optimize lead compounds for enhanced metabolic stability and binding affinity.